复发性呼吸道乳头状瘤病药物治疗的研究进展

沈梦雅; 肖洋; 马丽晶; 王军

doi:10.13201/j.issn.2096-7993.2020.12.022

复发性呼吸道乳头状瘤病药物治疗的研究进展

- 首都医科大学附属北京同仁医院耳鼻咽喉头颈外科耳鼻咽喉头颈科学教育部重点实验室(首都医科大学)(北京，100730)
基金项目:
北京市自然基金(No：7182036)和北京市医院管理中心儿科学科协同发展中心专项经费(No：XTCX201823)联合资助

详细信息

通讯作者: 王军，E-mail：wmzi2002@126.com

中图分类号: R734

收稿日期: 2019-11-13

刊出日期: 2020-12-05

Research progress in the adjunct therapy of recurrent respiratory papillomatosis

More Information

Corresponding author: WANG Jun, E-mail: wmzi2002@126.com

Received Date: 13 November 2019

Publish Date: 05 December 2020

摘要

- 乳头状瘤 /
- 呼吸道疾病 /
- 辅助治疗 /
- 药物治疗
Abstract: Recurrent respiratory papillomatosis (RRP) is a benign tumor of the respiratory tract caused by human papillomavirus (HPV) infection. At present, there is no cure for this disease, and mainly depends on surgical resection to relieve symptoms but cannot prevent recurrence. Multiple surgeries will bring heavy mental and economic burdens to patients and their families. Therefore, researchers are constantly seeking new treatments to reduce the number of operations and prevent recurrence. Hence, research on adjuvant therapy drugs has also been widely carried out, including bevacizumab, cidofovir, HPV vaccine, and Chinese medicine as an adjuvant drug according some reports. This article reviews the adjuvant treatment of RRP in recent years.
- papilloma /
- respiratory tract diseases /
- adjunct therapy /
- drug therapy

HTML全文

参考文献(41)

[1]	Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review[J]. Laryngoscope, 2008, 118(7): 1236-1247. doi: 10.1097/MLG.0b013e31816a7135
[2]	Mitsumoto GL, Bernardi F, Paes JF, et al. Juvenile-onset recurrent respiratory papillomatosis with pulmonary involvement and carcinomatous transformation[J]. Autops Case Rep, 2018, 8(3): e2018035. doi: 10.4322/acr.2018.035
[3]	Abramson AL, Steinberg BM, Winkler B. Laryngeal papillomatosis: clinical, histopathologic and molecular studies[J]. Laryngoscope, 1987, 97(6): 678-685.
[4]	Makiyama K, Hirai R, Matsuzaki H, et al. Assessment of human papilloma virus infection in adult laryngeal papilloma using a screening test[J]. J Voice, 2013, 27(2): 230-235. doi: 10.1016/j.jvoice.2012.10.014
[5]	夏忠芳, 杨占秋, 郭玉德, 等. 呼吸道乳头状瘤患儿血液细胞因子及免疫球蛋白的检测[J]. 临床耳鼻咽喉科杂志, 2002, 16(6): 292-294. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH200206022.htm
[6]	Papaioannou VA, Lux A, Voigt-Zimmermann S, et al. Treatment outcomes of recurrent respiratory papillomatosis: Retrospective analysis of juvenile and adult cases[J]. HNO, 2018, 66(Suppl 1): 7-15.
[7]	Bishai D, Kashima H, Shah K. The cost of juvenile-onset recurrent respiratory papillomatosis[J]. Arch Otolaryngol Head Neck Surg, 2000, 126(8): 935-939. doi: 10.1001/archotol.126.8.935
[8]	Tam S, Wu CF, Peng HL, et al. Cost of treating recurrent respiratory papillomavirus in commercially insured and medicaid patients[J]. Laryngoscope, 2020, 130(5): 1186-1194. doi: 10.1002/lary.28139
[9]	Ryan MA, Leu GR, Upchurch PA, et al. Systemic Bevacizumab(Avastin)for Juvenile-Onset Recurrent Respiratory Papillomatosis: A Systematic Review[J]. Laryngoscope, 2020. 〔Online ahead of print〕
[10]	Derkay CS, Bluher AE. Recurrent respiratory papillomatosis: update 2018[J]. Curr Opin Otolaryngol Head Neck Surg, 2018, 26(6): 421-425. doi: 10.1097/MOO.0000000000000490
[11]	Derkay CS, Bluher AE. Update on Recurrent Respiratory Papillomatosis[J]. Otolaryngol Clin North Am, 2019, 52(4): 669-679. doi: 10.1016/j.otc.2019.03.011
[12]	Hamdi O, Dome J, Zalzal G, et al. Systemic bevacizumab for end-stage juvenile recurrent respiratory papillomas: A case report[J]. Int J Pediatr Otorhinolaryngol, 2020, 128: 109706. doi: 10.1016/j.ijporl.2019.109706
[13]	Baday YI, Ongkasuwan J, Venkatramani R. Systemic bevacizumab for recurrent respiratory papillomatosis[J]. Int J Pediatr Otorhinolaryngol, 2020, 138: 110352. doi: 10.1016/j.ijporl.2020.110352
[14]	Carnevale C, Ferrán-De la Cierva L, Til-Pérez G, et al. Safe use of systemic bevacizumab for respiratory recurrent papillomatosis in two children[J]. Laryngoscope, 2019, 129(4): 1001-1004. doi: 10.1002/lary.27674
[15]	Bedoya A, Glisinski K, Clarke J, et al. Systemic Bevacizumab for Recurrent Respiratory Papillomatosis: A Single Center Experience of Two Cases[J]. Am J Case Rep, 2017, 18: 842-846. doi: 10.12659/AJCR.904416
[16]	Best SR, Mohr M, Zur KB. Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey[J]. Laryngoscope, 2017, 127(10): 2225-2229. doi: 10.1002/lary.26662
[17]	Xiong X, Smith JL, Chen MS. Effect of incorporation of cidofovir into DNA by human cytomegalovirus DNA polymerase on DNA elongation[J]. Antimicrob Agents Chemother, 1997, 41(3): 594-599. doi: 10.1128/AAC.41.3.594
[18]	Van Cutsem E, Snoeck R, Van Ranst M, et al. Successful treatment of a squamous papilloma of the hypopharynx-esophagus by local injections of(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine[J]. J Med Virol, 1995, 45(2): 230-235. doi: 10.1002/jmv.1890450221
[19]	Murono S, Nakanishi Y, Tsuji A, et al. Intralesional cidofovir injection for recurrent respiratory papillomatosis in Japan[J]. Auris Nasus Larynx, 2016, 43(5): 541-545. doi: 10.1016/j.anl.2016.01.005
[20]	Valera F, Maldonato L, Lima J, et al. Efficacy of cidofovir in recurrent juvenile respiratory papillomatosis[J]. Braz J Otorhinolaryngol, 2010, 76(6): 713-717. doi: 10.1590/S1808-86942010000600008
[21]	Jackowska J, Wojnowski W, Hashimoto A, et al. Voice improvement in patients with recurrent respiratory papillomatosis after combined treatment with cidofovir and CO2 laser surgery[J]. Lasers Med Sci, 2019, 34(7): 1433-1440. doi: 10.1007/s10103-019-02735-2
[22]	Izzedine H, Launay-Vacher V, Deray G. Antiviral drug-induced nephrotoxicity[J]. Am J Kidney Dis, 2005, 45(5): 804-817. doi: 10.1053/j.ajkd.2005.02.010
[23]	Bielecki I, Mniszek J, Cofała M. Intralesional injection of cidofovir for recurrent respiratory papillomatosis in children[J]. Int J Pediatr Otorhinolaryngol, 2009, 73(5): 681-684. doi: 10.1016/j.ijporl.2009.01.002
[24]	Tran MN, Galt L, Bashirzadeh F. Recurrent respiratory papillomatosis: the role of cidofovir[J]. Respirol Case Rep, 2018, 6(8): e00371. doi: 10.1002/rcr2.371
[25]	Wierzbicka M, Jackowska J, Bartochowska A, et al. Effectiveness of cidofovir intralesional treatment in recurrent respiratory papillomatosis[J]. Eur Arch Otorhinolaryngol, 2011, 268(9): 1305-1311. doi: 10.1007/s00405-011-1599-6
[26]	World Health Organization. Electronic address: sageexecsec@who. int. Human papillomavirus vaccines: WHO position paper, May 2017-Recommendations[J]. Vaccine, 2017, 35(43): 5753-5755. doi: 10.1016/j.vaccine.2017.05.069
[27]	Pham CT, Juhasz M, Sung CT, et al. The human papillomavirus vaccine as a treatment for human papillomavirus-related dysplastic and neoplastic conditions: A literature review[J]. J Am Acad Dermatol, 2020, 82(1): 202-212. doi: 10.1016/j.jaad.2019.04.067
[28]	Yiu Y, Fayson S, Smith H, et al. Implementation of Routine HPV Vaccination in the Management of Recurrent Respiratory Papillomatosis[J]. Ann Otol Rhinol Laryngol, 2019, 128(4): 309-315. doi: 10.1177/0003489418821695
[29]	Novakovic D, Cheng A, Zurynski Y, et al. A Prospective Study of the Incidence of Juvenile-Onset Recurrent Respiratory Papillomatosis After Implementation of a National HPV Vaccination Program[J]. J Infect Dis, 2018, 217(2): 208-212. doi: 10.1093/infdis/jix105
[30]	Langer C, Wittekindt C, Wolf G. 〔Laryngeal Recurrent Respiratory Papillomatosis: Current Aspects on Diagnosis and Therapy〕[J]. Laryngorhinootologie, 2019, 98(8): 577-587. doi: 10.1055/a-0896-9729
[31]	Yiu Y, Fayson S, Smith H, et al. Implementation of Routine HPV Vaccination in the Management of Recurrent Respiratory Papillomatosis[J]. Ann Otol Rhinol Laryngol, 2019, 128(4): 309-315. doi: 10.1177/0003489418821695
[32]	Makiyama K, Hirai R, Matsuzaki H. Gardasil Vaccination for Recurrent Laryngeal Papillomatosis in Adult Men: First Report: Changes in HPV Antibody Titer[J]. J Voice, 2017, 31(1): 104-106. doi: 10.1016/j.jvoice.2016.01.008
[33]	Hirai R, Makiyama K, Matsuzaki H, et al. Gardasil Vaccination for Recurrent Laryngeal Papillomatosis in Adult Men Second Report: Negative Conversion of HPV in Laryngeal Secretions[J]. J Voice, 2018, 32(4): 488-491. doi: 10.1016/j.jvoice.2017.07.017
[34]	Kin Cho Goon P, Scholtz LU, Sudhoff H. Recurrent respiratory papillomatosis(RRP)-time for a reckoning?[J]. Laryngoscope Investig Otolaryngol, 2017, 2(4): 184-186. doi: 10.1002/lio2.80
[35]	Young DL, Moore MM, Halstead LA. The use of the quadrivalent human papillomavirus vaccine(gardasil)as adjuvant therapy in the treatment of recurrent respiratory papilloma[J]. J Voice, 2015, 29(2): 223-229. doi: 10.1016/j.jvoice.2014.08.003
[36]	Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies[J]. Emerg Infect Dis, 2007, 13(1): 28-41. doi: 10.3201/eid1301.060438
[37]	潘晓菲, 肖洋. 人乳头状瘤病毒疫苗防治呼吸道乳头状瘤病的研究现状[J]. 临床耳鼻咽喉头颈外科杂志, 2019, 33(2): 189-192. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH201902025.htm
[38]	Okubo K, Saito K, Fukuda H, et al. Traditional Chinese Medicine for treatment of laryngeal papillomatosis[J]. J Altern Complement Med, 2010, 16(4): 427-433. doi: 10.1089/acm.2009.0314
[39]	马捷, 李峰, 王军, 等. 中药辅助治疗儿童喉乳头状瘤病的疗效观察[J]. 中国中西医结合耳鼻咽喉科杂志, 2012, 20(3): 215-217. https://www.cnki.com.cn/Article/CJFDTOTAL-XYJH201203024.htm
[40]	陆颖鑫, 王军, 李峰, 等. 中药对小儿复发性呼吸道乳头状瘤中人乳头状瘤病毒含量的影响[J]. 现代中医临床, 2015, 22(5): 38-41. https://www.cnki.com.cn/Article/CJFDTOTAL-JZYL201505011.htm
[41]	王慧, 王军, 肖洋. 中药联合手术治疗成人复发性呼吸道乳头状瘤的临床疗效及血清免疫学改变相关研究[J]. 临床耳鼻咽喉头颈外科杂志, 2018, 32(2): 109-112. https://www.cnki.com.cn/Article/CJFDTOTAL-LCEH201802008.htm